FOXO4-DRI

Comprehensive Research Analysis - Senolytic Peptide for Cellular Aging & Senescent Cell Clearance

Classification: Senolytic Peptide, FOXO4/p53 Interaction Blocker Amino Acid Sequence: H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH (D-retro-inverso configuration) Chemical Formula: C₂₂₈H₃₈₈N₈₆O₆₄ Molecular Weight: 5,358.05 Da Research Status: Preclinical (Animal/In Vitro Studies Only) WADA Status: Likely Prohibited (S0 Unapproved Substances)

1. Executive Summary

FOXO4-DRI (also known as Proxofim) is a synthetic D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 protein interaction. Developed as a targeted senolytic agent, it represents a novel approach to combating cellular aging by eliminating "zombie cells" that contribute to age-related diseases and tissue dysfunction.

CRITICAL: No human clinical trials have been completed. All available data comes from animal studies and in vitro human cell cultures. This peptide has no published data on human use.

Key Research: Landmark 2017 mouse study demonstrated restoration of tissue homeostasis, improved kidney function, and fur density recovery in aged mice without observable side effects. In vitro studies showed selective removal of senescent human chondrocytes.

Goal Relevance:

I want to slow down aging and improve my overall vitality.
I'm looking for ways to enhance my skin health and reduce signs of aging.
I need help with joint pain and improving my mobility as I age.
I'm interested in boosting my immune system and reducing inflammation.
I want to support my body's natural ability to repair and rejuvenate tissues.
I'm seeking a way to improve my energy levels and combat fatigue associated with aging.
I'm interested in exploring options for improving my cognitive function and mental clarity as I get older.

Goal Archetype Integration

Primary Goal Alignment

Goal	Relevance	Role of FOXO4-DRI
Fat Loss	Low	No direct mechanism; senescent cell clearance may indirectly improve metabolic tissue function
Muscle Building	Low/Moderate	Clearance of senescent satellite cells may improve regenerative capacity in aged muscle
Longevity	High	Primary application - selective elimination of senescent cells that drive aging and "inflammaging"
Healing/Recovery	High	Removes senescent cells that impair tissue repair; demonstrated in pulmonary fibrosis and chemotherapy recovery models
Cognitive Optimization	Moderate	Limited by blood-brain barrier penetration (large molecule ~5,358 Da); peripheral senescent cell clearance may reduce systemic inflammation affecting cognition
Hormone Optimization	Moderate	Mouse studies showed alleviation of age-related testosterone insufficiency by targeting senescent Leydig cells

When This Compound Makes Sense

Advanced biological age (60+) with accumulated senescent cell burden contributing to frailty, tissue dysfunction, or chronic inflammation
Post-chemotherapy recovery to clear therapy-induced senescent cells that promote adverse effects and accelerated aging phenotypes
Age-related fibrotic conditions - preclinical evidence in pulmonary fibrosis models
Joint degeneration - in vitro evidence of selective senescent chondrocyte removal
Individuals seeking targeted senolytic approach who want p53-mediated apoptosis pathway vs. BCL-2 family inhibition (D+Q/navitoclax)
Research-oriented individuals comfortable with preclinical-only evidence and experimental protocols

When to Choose Something Else

Budget constraints: FOXO4-DRI costs $200-300 per cycle vs. <$50 for dasatinib + quercetin
Neurological focus: Large peptide (~5,358 Da) poorly penetrates blood-brain barrier; D+Q (dasatinib 488 Da, quercetin 302 Da) or fisetin (286 Da) are better choices for CNS senescent cell targeting
Desire for clinical validation: Dasatinib + quercetin has Phase I/II human trial data; FOXO4-DRI has no published human trials
Simplicity preference: Oral D+Q or fisetin vs. subcutaneous injection preparation and administration
First-time senolytic users: Start with clinically studied compounds before experimental peptides

2. Chemical Structure & Composition

Molecular Weight: 5,358.05 Da Formula: C₂₂₈H₃₈₈N₈₆O₆₄ CAS Number: 2460055-10-9

Structure: D-Retro-Inverso (DRI) peptide constructed from D-amino acids (mirror-image forms of natural L-amino acids) in reverse sequence. The peptide comprises approximately 34 amino acids in its core disrupting sequence.

Full Sequence: H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH (lowercase letters denote D-amino acids)

DRI Configuration Benefits:

Significantly increased resistance to enzymatic degradation
Extended half-life and bioavailability
Enhanced stability in biological systems
Reduced susceptibility to normal physiologic clearance mechanisms

Alternative Names: Proxofim, FOXO4a, AFX, AFX1, MLLT7

3. Mechanism of Action

Primary Mechanism: FOXO4-p53 Interaction Disruption

Senescent Cell Targeting: In senescent cells, FOXO4 maintains viability by binding to p53 at DNA damage sites, preventing p53 nuclear exclusion and subsequent apoptosis. FOXO4-DRI competitively blocks the FOXO4-p53 interaction, disrupting this protective mechanism.
p53 Nuclear Exclusion: Once the FOXO4-p53 bond is disrupted, active p53 is excluded from the nucleus and directed to mitochondria, where it initiates cell-intrinsic apoptosis via caspase-dependent pathways.
Selective Senescent Cell Apoptosis: At low doses, FOXO4-DRI appears more selective toward senescent cells than pan-BCL inhibitors like ABT-737. The FOXO4-p53 axis was identified as pivotal in maintaining senescent cell viability, making it an ideal therapeutic target.
Transcription-Independent Apoptosis: Released p53 induces transcription-independent apoptosis at mitochondria, bypassing normal cell cycle checkpoints and selectively eliminating senescent cells without harming healthy tissue.

Cellular Senescence Context: During senescence, FOXO4 and p53 localize to PML bodies and physically interact, upregulating p21 transcription (the senescence master regulator). FOXO4-DRI interrupts this pro-survival signaling.

4. Pharmacokinetics

CRITICAL CAVEAT: Human pharmacokinetic data does not exist. The following is extrapolated from animal studies and D-amino acid peptide properties.

Absorption:

Subcutaneous route: Excellent bioavailability in mice
Oral route: Low bioavailability in mice
Administration: Subcutaneous or intraperitoneal (animal studies)

Half-Life:

DRI configuration significantly extends half-life through resistance to proteolytic degradation
Specific numerical values not disclosed in literature
Daily dosing regimens suggest relatively short half-life (hours to low days)

Distribution:

Cell-permeable peptide; crosses cellular membranes
Human FOXO4 protein expressed in testis, placenta, muscle per Human Protein Atlas
Targets senescent cells throughout tissues

Metabolism:

Reduced susceptibility to proteolytic degradation due to D-amino acid composition
Remains in body for extended periods vs. natural L-peptides
Specific metabolic pathways not characterized

Clearance: Renal excretion presumed; clearance kinetics not established in humans.

5. Dosing Protocols

Animal Research Dosing

Mouse Studies: 5 mg/kg intraperitoneally, three doses administered every other day.

Theoretical Human Protocols (Unvalidated)

Ben Greenfield Protocol:
- 3 mg subcutaneous every other day for 6 days (3 doses total)
- Repeat 1–3 times per year
Daily Low-Dose Protocol:
- 33–50 mcg subcutaneous daily
- Duration unspecified
Alternative Weekly Protocol:
- 0.3–0.5 mg (30–50 units via insulin syringe) subcutaneous daily for 7 days
- Administered every other week

Body Weight Adjustments: Not established; theoretical protocols do not adjust for body weight.

IMPORTANT: These protocols necessitate extensive clinical validation before practical application.

Age-Stratified Dosing

Rationale: Senescent cell burden increases with age. Studies show p16-positive and p21-positive cells accumulate in skin, pancreas, kidney, brain cortex, liver, spleen, and intestine with advancing age. Older individuals likely have greater senescent cell loads requiring clearance, but may also have reduced clearance capacity.

Age Bracket	Starting Dose	Adjustment	Rationale
20-35	Not recommended	N/A	Minimal senescent cell burden; senolytics generally not indicated
35-50	Conservative (if indicated)	1-2 mg subcutaneous, 3 doses EOD	Lower senescent burden; use only with specific indication (post-chemo, chronic inflammation)
50-65	Standard theoretical	2-3 mg subcutaneous, 3 doses EOD	Accumulating senescent cells; primary target demographic for anti-aging applications
65+	Standard to conservative	2-3 mg subcutaneous, 3 doses EOD; extend to 1-2x/year	Highest senescent burden but consider slower peptide clearance; longer intervals between cycles

Sex-Specific Considerations

Males:

Evidence in aged male mice showed FOXO4-DRI alleviated testosterone insufficiency by targeting senescent Leydig cells
May have particular relevance for age-related hypogonadism resistant to conventional TRT
No human data on reproductive effects

Females:

No sex-specific dosing data available
Theoretical consideration: menopause accelerates senescent cell accumulation; post-menopausal women may be priority candidates
Avoid during pregnancy/lactation (unknown fetal/infant effects)
Hormonal cycle considerations: No data; theoretical preference for follicular phase administration to minimize hormonal interference

Senescent Cell Burden Assessment

Before initiating FOXO4-DRI, consider baseline assessment of senescent cell burden:

Indicator	Suggests Higher Burden	Suggests Lower Burden
Chronological age	>60 years	<40 years
Inflammatory markers (hs-CRP, IL-6)	Elevated	Normal
Prior chemotherapy/radiation	Yes	No
Chronic diseases (diabetes, CVD, fibrosis)	Present	Absent
Physical function decline	Accelerated	Age-appropriate
Epigenetic age acceleration	Biological > chronological	Biological <= chronological

6. Clinical Research & Evidence

Human Clinical Trials

STATUS: No comprehensive human clinical trials have been completed. No human clinical safety or efficacy data currently exist.

Animal Research

Landmark 2017 Study (Baar et al., Cell):

Aged mice treated with FOXO4-DRI (5 mg/kg, 3 doses every other day)
Results:
- Restoration of tissue homeostasis after chemotherapy
- Improved kidney function in naturally aged mice
- Recovery of fur density and physical fitness
- Destruction of senescent cells without observable side effects

Testosterone Secretion Study:

FOXO4-DRI alleviated age-related testosterone insufficiency by targeting senescent Leydig cells in aged mice

Pulmonary Fibrosis Study:

FOXO4-DRI targeted myofibroblasts and ameliorated bleomycin-induced pulmonary fibrosis in mice via ECM-receptor interaction pathway

In Vitro Human Cell Studies

Human Chondrocyte Study:

FOXO4-DRI selectively removed senescent cells from in vitro expanded human chondrocytes
Increased p21 levels in pre-treated groups (potential cellular stressor)

Keloid Fibroblast Study:

FOXO4-DRI induced apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

Research Limitations

CRITICAL:

No published data on human use at all
A lot more work needed for comprehensive safety profile
Long-term effects unknown
Optimal dosing, administration routes, treatment frequency undetermined

Evidence Quality: Moderate preclinical evidence (strong animal studies, promising in vitro human cell data); no Phase I/II/III human trials.

7. Safety Profile

Common Side Effects (Speculative):

Injection site reactions (localized pain, redness, swelling)
Potential systemic immune activation
Metabolic effects: Fatigue, loss of appetite (theoretical)

Serious Adverse Events:

No long-term safety data in humans
Potential off-target effects unknown
Risk of immune responses unclear

Animal Safety:

In Vitro Observations:

Increased p21 levels in FOXO4-DRI pre-treated human chondrocytes, suggesting senolytics might stress non-senescent cells

Contraindications (Theoretical):

Pregnancy/breastfeeding (unknown fetal/infant effects)
Active cancer (senescent cells can suppress tumor growth; their removal theoretically risky)
Severe immune dysfunction
Peptide hypersensitivity

Long-Term Safety: Completely unknown. Extensive further research required.

Drug Interactions - Comprehensive

CRITICAL CAVEAT: No formal drug interaction studies exist for FOXO4-DRI. The following is based on mechanism of action considerations, p53 pathway pharmacology, and theoretical extrapolation from senolytic class effects.

Prescription Medications

Drug Class	Interaction	Severity	Management
Chemotherapeutics	Complex; chemo induces therapy-induced senescent cells (TIS). FOXO4-DRI designed to clear TIS. Research shows restoration of tissue homeostasis post-chemotoxicity in mice	Moderate	Coordinate timing with oncologist; use AFTER chemotherapy course completion to clear TIS, not during active treatment
Immunosuppressants (cyclosporine, tacrolimus, sirolimus)	Theoretical concern: SASP clearance affects immune signaling; senescent cells have immunomodulatory effects	Unknown	Use with extreme caution; senolytic effects on transplant tolerance unknown
MDM2 inhibitors (idasanutlin, milademetan)	Synergistic p53 activation; both stabilize/activate p53 through different mechanisms	Major	Avoid combination; excessive p53 activation could cause widespread apoptosis beyond senescent cells
Bcl-2 inhibitors (venetoclax, navitoclax)	Additive/synergistic senolytic effect via different apoptotic pathways	Moderate	If combining senolytics, use extreme caution with lower doses; risk of excessive cell death
p53 stabilizers	Enhanced senolytic effect but reduced selectivity	Moderate-Major	Avoid concurrent use; selectivity depends on FOXO4-p53 axis in senescent cells only
Corticosteroids (prednisone, dexamethasone)	May suppress SASP inflammatory signaling; could mask senolytic response indicators	Minor	May be used; monitor response carefully
NSAIDs	May suppress SASP inflammatory components; minimal interaction expected	Minor	Safe to use; may blunt inflammatory marker response to senolytic clearance
Anticoagulants (warfarin, DOACs)	No known interaction; monitor for injection site bleeding	Minor	Standard precautions; apply pressure to injection sites

Cancer Therapy Considerations

Cancer Status	Recommendation	Rationale
Active malignancy (untreated)	AVOID	Senescent cells contribute to tumor surveillance; removal may promote progression
During chemotherapy/radiation	AVOID	Treatment effect depends partly on inducing senescence; premature clearance could reduce efficacy
Post-treatment (>3-6 months)	Consider with oncologist	Research supports clearance of therapy-induced senescent cells to reduce long-term adverse effects
Cancer remission (>2 years)	May consider	Clearance of lingering TIS may reduce relapse risk and accelerated aging; theoretical benefit
Carcinoma in situ/pre-malignant	AVOID	Senescent program may be containing transformation

Other Compounds (Stacking)

Compound	Interaction	Effect	Recommendation
Dasatinib + Quercetin	Additive senolytic via BCL-2/BCL-XL pathway	Enhanced senescent cell clearance	Do NOT combine in same cycle; use sequentially if desired (D+Q oral, then FOXO4-DRI injection in separate cycles)
Fisetin	Additive senolytic (BCL-2 family)	Enhanced clearance	Sequential use preferred; do not stack multiple senolytics
Navitoclax (ABT-263)	Potent BCL-2/BCL-XL/BCL-W inhibitor + FOXO4-DRI	Potentially excessive apoptosis	Avoid combination; both are aggressive senolytics
Rapamycin/mTOR inhibitors	Senomorphic (reduces SASP) vs. senolytic (kills cells)	Different mechanisms; may be complementary	May use in separate cycles; rapamycin between senolytic pulses
Metformin	Senomorphic/metabolic effects	May reduce senescent cell formation	Safe to continue; complementary mechanism
NAD+ precursors (NMN, NR)	Support cellular energy/repair	Supports healthy cell recovery post-senolytic clearance	Safe; may enhance recovery from senolytic pulse
BPC-157 / TB-500	Tissue repair peptides	May support tissue healing after senescent cell clearance	Theoretical synergy; use in recovery phase after FOXO4-DRI cycle

Supplements

Supplement	Interaction	Notes
Quercetin (standalone)	Mild senolytic; may have additive effect	Low concern at standard supplement doses (500-1000mg); high doses (>2000mg) approach senolytic threshold
Fisetin (standalone)	Senolytic at high doses	Low concern at standard doses; avoid mega-dosing during FOXO4-DRI cycle
Resveratrol	SIRT1 activator; affects p53 acetylation	Theoretical interaction; may modulate FOXO4-DRI effect
Curcumin	Anti-inflammatory; mild senomorphic	Safe; may support SASP reduction
Fish oil/Omega-3s	Anti-inflammatory	Safe; supports healthy inflammatory response
Vitamin D	Immune modulation	Safe; optimize levels for immune health

Foods/Timing

Food/Timing	Interaction	Notes
High-quercetin foods (capers, onions, berries)	Minimal interaction at dietary levels	Safe; food-level quercetin is sub-senolytic
Grapefruit/CYP3A4 inhibitors	Unknown; peptides generally bypass CYP metabolism	Likely no interaction; peptides not metabolized by CYP450
Fasting state	May enhance autophagy/cellular clearance	Theoretical benefit; some prefer administration during fasted state
Fed state	No known difference	Administration timing flexible
Alcohol	May impair cellular repair processes	Avoid heavy consumption during senolytic cycles

8. Administration & Practical Application

Route: Subcutaneous injection (based on animal studies) Injection Sites: Abdomen, thigh, upper arm (subcutaneous fat) Reconstitution: Lyophilized powder reconstituted with bacteriostatic water Injection Technique:

Use 27–30 gauge insulin needles
Rotate injection sites to prevent tissue damage
Maintain sterile technique

Timing: No established human protocols; animal studies used alternate-day dosing.

Supervision: Should ONLY be used under medical supervision for research purposes. Not recommended for unsupervised use.

9. Storage & Stability

Lyophilized Powder:

Store at -20°C to -80°C (long-term optimal)
Refrigerate 2–8°C (short-term acceptable)
Protect from light and moisture

Reconstituted Solution:

Refrigerate 2–8°C immediately after reconstitution
Use within 28 days when mixed with bacteriostatic water
Use within 3–5 days with sterile water
Avoid freeze-thaw cycles

Stability: DRI configuration provides enhanced stability compared to natural L-peptides.

Bloodwork Impact & Monitoring

CRITICAL CAVEAT: No validated human biomarker panels exist for FOXO4-DRI monitoring. The following is based on senescence biology research, SASP composition, and theoretical extrapolation from senolytic studies.

Expected Marker Changes

Marker	Expected Change	Direction	Timeline
hs-CRP	Transient increase during clearance, then decrease	↑ then ↓	Spike 1-3 days post-dose; reduction 2-4 weeks post-cycle
IL-6	Transient elevation (SASP release) then reduction	↑ then ↓	Similar to hs-CRP; reflects SASP clearance
IL-8	Part of SASP; may decrease with senescent cell clearance	↓	2-4 weeks post-cycle
TNF-alpha	SASP component; expected reduction	↓	2-4 weeks post-cycle
MMP-3/MMP-12	Matrix metalloproteinases elevated in senescence; MMP12 particularly age-associated	↓	Weeks to months
p16INK4a (if measured)	Direct senescence marker; should decrease	↓	Variable; tissue-dependent
IL-23R	Emerging circulating senescence biomarker; reversed by senotherapeutics	↓	Weeks post-treatment
CCL5/RANTES	Inflammatory chemokine; reversed by senolytic treatment in studies	↓	Weeks post-treatment
GDF-15	Stress/senescence marker; often elevated in aging	↓	Weeks to months

Senescence-Specific Markers (Research/Specialized)

Marker	Significance	Availability
SA-beta-galactosidase (SA-β-gal)	Classic senescence marker; measures lysosomal enzyme activity	Tissue biopsy only; not blood test
p16INK4a mRNA (blood)	T-cell senescence marker; correlates with biological age	Specialized labs (e.g., Oisin Biotechnologies panels)
p21 (CDKN1A)	Cell cycle arrest marker; elevated in senescence	Tissue/research only
Lamin B1	Nuclear envelope protein; decreased in senescence	Research only
HMGB1	Alarmin released by senescent cells	Specialized testing

Monitoring Schedule

Timepoint	Required Tests	Optional Tests
Baseline (Pre-cycle)	CBC, CMP, hs-CRP, IL-6, liver enzymes (AST, ALT), kidney function (BUN, creatinine)	GDF-15, TNF-alpha, lipid panel, fasting glucose/insulin
During cycle (Day 3-5)	None required	hs-CRP (expect transient elevation)
2 weeks post-cycle	hs-CRP, IL-6	TNF-alpha, CBC
4-6 weeks post-cycle	CBC, CMP, hs-CRP, IL-6, liver enzymes, kidney function	Full inflammatory panel, GDF-15
3 months post-cycle	Repeat baseline panel	Epigenetic age testing if tracking biological age
Ongoing (Annual)	Standard health panels + inflammatory markers	Epigenetic clocks, specialized senescence panels

Red Flags in Labs

Finding	Action
Sustained CRP elevation >2 weeks	May indicate incomplete senescent cell clearance or inflammatory complication; hold further cycles; investigate cause
Liver enzyme elevation (AST/ALT >3x ULN)	Hold treatment; assess for hepatotoxicity; likely unrelated but requires evaluation
Acute kidney function decline	Hold treatment; evaluate cause; paradoxical given kidney improvement seen in mouse studies
Significant CBC changes (WBC <3.0 or >15.0)	Evaluate for infection or hematologic effect; hold further cycles
New onset fatigue + elevated inflammatory markers	May indicate "senolytic flu" from rapid SASP release; supportive care; typically resolves

Labs + Symptoms Integration

Lab Finding	Symptom	Interpretation	Action
↑ CRP/IL-6	Flu-like symptoms, fatigue, malaise	"Senolytic flu" - expected transient effect from SASP release during senescent cell death	Supportive care; rest; anti-inflammatory support (omega-3, curcumin); typically resolves in days
↓ CRP/IL-6	Improved energy, reduced joint pain	Successful senescent cell clearance; reduced inflammaging	Continue monitoring; note improvements
Normal CRP	No symptom change	Possible insufficient senescent cell burden or inadequate dosing	Reassess indication; consider if senolytic therapy appropriate for this individual
↑ CRP	Injection site reaction	Local inflammatory response	Rotate injection sites; proper sterile technique; may use ice post-injection
Stable/↓ inflammatory markers	Improved skin quality, function	Tissue homeostasis restoration	Document improvements; supports continued protocol

Epigenetic Age Monitoring (Advanced)

For individuals tracking biological age, consider:

Test	Provider	Frequency	Notes
GrimAge clock	TruDiagnostic, Elysium	Baseline + 6 months post-cycle	Research shows D+Q senolytic treatment effects on methylation clocks
DunedinPACE	TruDiagnostic	Baseline + 6 months	Measures pace of aging; may show slowing
Inflammage	Various	Baseline + 3-6 months	Inflammation-based aging marker

11. Product Cross-Reference

Core Peptides Equivalent:

Product: FOXO4-DRI 10mg
Price: $235.00 ($23.50/mg)
Bulk Pricing: 5–8 units = $223.25 (5% off); 9+ units = $211.50 (10% off)
Purity: >99%
Form: Lyophilized powder
SKU: P-FOXO4-10
Molecular Weight: 5,358.05 g/mol (verified)
Molecular Formula: C₂₂₈H₃₈₈N₈₆O₆₄ (verified)

Epiq Aminos: Product availability and pricing to be confirmed via https://orange-shrew-635172.hostingersite.com/

Chemical Validation: Molecular formula and weight match across scientific literature and vendor specifications.

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

_ ] It's just a matter of time. Tick- tock. Tick tock, man. And that's it. No micro doing. Start at 0. 25 mg per week. Titrate up, which means add a little more week by week by 0. 25 to.
doing. Start at 0. 25 mg per week. Titrate up, which means add a little more week by week by 0. 25 to. 5 milligrams based on your tolerance. So next week, if you're at 0.

Stacking Insights

n't. You can't. They do not exist. The MK677 study, I debunked that a long time ago and I proved it with the science and the study itself. I ripped it apart.

12. References & Citations

Protocol Integration

Cycling Protocols (Senolytic Pulses)

Rationale for Intermittent Dosing: Research demonstrates that senolytics are effective when administered intermittently because:

Senescent cells are in replicative arrest (not dividing)
It takes 1-6+ weeks for cells to become senescent and develop SASP
Brief exposure (hours) is sufficient to trigger irreversible apoptosis in susceptible senescent cells
Extended half-life of DRI peptides supports intermittent dosing

FOXO4-DRI Cycling Options:

Protocol	Cycle Structure	Frequency	Best For
Standard Pulse	3 doses EOD (Days 1, 3, 5)	Every 3-4 months	General anti-aging, moderate senescent burden
Intensive Initial	3 doses EOD, repeat in 4 weeks, then quarterly	First year then quarterly	High senescent burden, post-chemotherapy
Annual Maintenance	3 doses EOD	1-2x per year	Lower burden, younger individuals, maintenance
Seasonal	3 doses EOD	Spring + Fall (2x/year)	Aligns with natural rhythms; easy to remember

Stacking with Other Senolytics

Sequential Senolytic Protocols

Stack Approach	Protocol	Rationale
FOXO4-DRI First, D+Q Later	FOXO4-DRI cycle, wait 4-6 weeks, then D+Q cycle	FOXO4-DRI targets p53-pathway; D+Q targets BCL-2 family; covers different senescent cell populations
D+Q First, FOXO4-DRI Later	D+Q cycle (2-3 days), wait 4-6 weeks, then FOXO4-DRI	Start with clinically validated approach, add peptide for deeper clearance
Annual Rotation	Alternate between FOXO4-DRI and D+Q every 6 months	Varied mechanism coverage; practical simplicity

Multi-Phase Annual Protocol (Advanced)

Example: Comprehensive Senolytic Year

Month	Intervention	Notes
January	Baseline labs + epigenetic age	Establish baseline inflammatory markers, biological age
February	FOXO4-DRI pulse (3 doses EOD)	p53-pathway senolytic
March	Recovery + labs (2 weeks post)	Monitor inflammatory response
April-May	Senomorphic support (rapamycin, metformin)	Reduce new senescent cell formation
June	Fisetin cycle (2-3 days high dose)	BCL-2 pathway, natural compound
July	Recovery + labs	Monitor response
August-September	Senomorphic support	Maintenance phase
October	D+Q cycle (2 days)	Clinically validated combination
November	Recovery + labs	End-of-year assessment
December	Epigenetic age retest	Compare to baseline

Timing Considerations

If Also Taking	Timing with FOXO4-DRI
Dasatinib + Quercetin	Separate by minimum 4-6 weeks; do not combine in same cycle
Fisetin	Separate by minimum 4-6 weeks
Rapamycin	Can continue between senolytic pulses; hold during active senolytic cycle
Metformin	Safe to continue; complementary mechanism
NAD+ precursors (NMN/NR)	Safe; may enhance cellular recovery post-clearance
BPC-157 / TB-500	Start 1 week post-FOXO4-DRI cycle to support tissue repair
GHK-Cu	Topical safe anytime; systemic may support skin regeneration post-clearance
Thymosin Alpha-1	May support immune function; safe to use between cycles

Integration with Pillars

Pillar	Integration Point
Nutrition	Support autophagy with periodic fasting; quercetin-rich foods (onions, capers, berries) provide mild senomorphic effect; anti-inflammatory diet (Mediterranean) reduces SASP; ensure adequate protein for tissue repair post-clearance
Activity	Moderate exercise supports senescent cell clearance; intense exercise temporarily induces senescence markers - may be fine but consider timing; maintain activity during recovery phase
Sleep	Critical for cellular repair; optimize sleep during and after senolytic cycles; poor sleep accelerates senescence
Stress	Chronic stress accelerates cellular aging; stress management supports senolytic benefits; consider cycle timing during lower-stress periods
Supplementation	Omega-3s and curcumin support anti-inflammatory environment; vitamin D optimizes immune function; avoid high-dose quercetin/fisetin supplements during FOXO4-DRI to prevent stacking

Recovery Protocol Post-Cycle

Week 1-2 Post-FOXO4-DRI:

Expect possible "senolytic flu" (fatigue, mild malaise)
Increase rest; reduce intense exercise
Support with anti-inflammatory foods
Monitor for excessive injection site reactions

Week 2-4 Post-Cycle:

Energy typically returns/improves
Resume normal activity
Consider tissue-supportive peptides (BPC-157, TB-500) if indicated
Check labs at 2-week mark

Week 4+ Post-Cycle:

Full activity resumption
Note subjective improvements (energy, cognition, skin, joint comfort)
Document response for future cycle planning
Schedule next cycle based on chosen protocol

Response Assessment

Response Level	Observations	Next Steps
Strong Responder	Noticeable energy improvement, reduced joint pain, improved skin, ↓ inflammatory markers	Continue protocol; may extend intervals between cycles
Moderate Responder	Subtle improvements; mild inflammatory marker changes	Continue protocol; consider baseline senescent burden assessment
Non-Responder	No subjective or objective changes	Reassess if senolytic therapy appropriate; consider alternative senolytic (D+Q); ensure proper storage/handling of peptide
Adverse Responder	Prolonged fatigue, sustained inflammation, concerning lab changes	Hold further cycles; investigate cause; medical evaluation

Document Version: 2.0 Last Updated: January 5, 2026 Development Status: Preclinical; No Human Trials Completed For Research and Educational Purposes Only